Health Care [ 4/12 ] | Biotechnology [ 11/75 ]
NASDAQ | Common Stock
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States.
The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC.
It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC.
The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020.
CG Oncology, Inc. was founded in 2010 and is headquartered in Irvine, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 27, 26 | -0.51 Decreased by -10.87% | -0.48 Decreased by -6.25% |
| Nov 14, 25 | -0.57 Decreased by -90.00% | -0.55 Decreased by -4.26% |
| Aug 8, 25 | -0.54 Decreased by -92.86% | -0.44 Decreased by -22.12% |
| May 13, 25 | -0.45 Decreased by -25.00% | -0.37 Decreased by -20.32% |
| Mar 28, 25 | -0.46 Decreased by -39.01% | -0.45 Decreased by -2.22% |
| Nov 12, 24 | -0.30 | -0.42 Increased by +28.57% |
| Aug 8, 24 | -0.28 | -0.40 Increased by +30.00% |
| May 9, 24 | -0.36 | -0.29 Decreased by -24.14% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 2.32 M Increased by +409.21% | -41.31 M Decreased by -29.91% | Decreased by -1.78 K% Increased by +74.49% |
| Sep 30, 25 | 1.67 M Increased by +3.77 K% | -43.81 M Decreased by -114.69% | Decreased by -2.63 K% Increased by +94.46% |
| Jun 30, 25 | 0.00 Decreased by -100.00% | -41.43 M Decreased by -119.16% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 52.00 K Decreased by -90.17% | -34.45 M Decreased by -103.47% | Decreased by -66.25 K% Decreased by -1.97 K% |
| Dec 31, 24 | 456.00 K Increased by +45.50 K% | -31.80 M Decreased by -97.31% | Decreased by -6.97 K% Increased by +99.57% |
| Sep 30, 24 | 43.00 K Increased by +377.78% | -20.41 M Decreased by -73.39% | Decreased by -47.45 K% Increased by +63.71% |
| Jun 30, 24 | 111.00 K Increased by +N/A% | -18.90 M Decreased by -62.77% | Decreased by -17.03 K% Decreased by N/A% |
| Mar 31, 24 | 529.00 K Increased by +172.68% | -16.93 M Decreased by -95.36% | Decreased by -3.20 K% Increased by +28.36% |